Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellProtect + Isatuximab vs Isatuximab in MM Maintenance
NCT04558931Phase 2Recruiting
- Sponsor
- Karolinska Institutet
- Start
- Jun 2021
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CellProtect in multiple myeloma (MM) (2 arms), sponsored by Karolinska Institutet. Primary endpoints: Overall Response Rate up to 96 months and Minimal Residual Disease Negativity Rate at 24 months. Started Jun 2021; status: recruiting.
02
Drugs
CellProtect
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04558931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04558931.